United Guardian Q3 2026 earnings
Net sales and net income surged in the third quarter, driven by a 187% jump in cosmetic ingredient sales and a 29% increase in pharmaceuticals.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $3,494,780 | +54% | +12.4% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.20 | +233% | +25% | Ex. 99.1, income statement |
| Net income | $930,912 | +247% | +27.8% | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Cosmetic ingredients | +187% YoY | +187% | N/A | Driven by increased purchases from Ashland Specialty Ingredients (ASI) |
| Pharmaceuticals | +29% YoY | +29% | N/A | Renacidin® was the primary driver |
| Medical lubricants | +20% YoY | +20% | N/A | Driven by increased purchases from a customer in India |
Margins and costs
- Gross margin 46.4% (prior 46.3%, change +0.1 pp)
- Operating expenses $644,539 (+3.8% YoY)
- One-offs in the quarter Net (loss) gain on marketable securities of $7,916; Settlement income of $339,493; Gain on sale of asset of $8,310
- Effective tax rate 20.7% (prior-year 17.8%, year-to-date 20.7%)
- Non-GAAP bridge No reconciliation provided.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Weighted average shares | 4,594,319 | 4,594,319 | 4,594,319 | 0.0% |
Guidance
not stated in the 8-K
What drove it
- Revenue story Cosmetic ingredient sales surged 187% YoY, pharmaceuticals grew 29% YoY, and medical lubricants grew 20% YoY.
- EPS story EPS increased 233% YoY, driven by a 247% increase in net income.
- One-off check Net (loss) gain on marketable securities of $7,916; Settlement income of $339,493; Gain on sale of asset of $8,310.
The good
- Net sales increased 54% YoY
- Net income increased 247% YoY
- Cosmetic ingredient sales surged 187% YoY
The bad
- none
The ugly
- none
Open questions
- The release does not disclose the specific revenue contribution or share of total sales for each segment.
- The release does not provide a reconciliation of GAAP to non-GAAP earnings.
Full release
United Guardian (UG) earnings release, November 9, 2026
United-Guardian Reports Higher Third Quarter Earnings
HAUPPAUGE, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and first nine months of 2026. Third quarter net sales increased by 54% from $2,264,261 in 2025 to $3,494,780 in 2026, with net income increasing 247% from $268,441 ($0.06 per share) to $930,912 ($0.20 per share). Net sales for the nine-month period ended September 30 th increased by 25% from $7,583,613 in 2025 to $9,475,269 in 2026, and net income increased by 70% from $1,456,162 ($0.32 per share) to $2,478,393 ($0.54 per share).
Donna Vigilante, President of United-Guardian, stated, “I am very excited to report that our third quarter was exceptionally strong, with pharmaceuticals, personal care and medical lubricants all posting sales increases. Pharmaceutical sales grew 29% compared with the same period in 2025, driven primarily by Renacidin®, our most important pharmaceutical product. The increase was partly attributable to the expanded formulary coverage we achieved earlier this year. In addition, cosmetic ingredient sales surged 187% over the same period in 2025, led by increased purchases from Ashland Specialty Ingredients (“ASI”), our largest marketing partner. Medical lubricants also grew 20% compared with the same period in 2025, reflecting increased purchases from one of our customers in India.”
“I am very pleased with our performance for the first nine months of 2026. Our growth initiatives have produced encouraging results, and we plan to continue building on this progress. In pharmaceuticals, we are in the process of determining which marketing efforts to deploy to increase awareness of Renacidin among healthcare professionals. In personal care, we have a new product in late-stage development that we plan to launch early next year. We are hopeful that our continued efforts will drive further growth and lead to increased sales.”
United-Guardian is a diversified life sciences and personal care ingredients company that develops, manufactures, and globally commercializes proprietary pharmaceuticals, medical lubricants, specialty cosmetic ingredients and consumer wellness products.
Financial statements
Income Statement
Financial Results for the
| Financial Results for the – Three and Nine Months Ended – September 30, 2026 and 2025 – STATEMENTS OF INCOME – (unaudited) – THREE MONTHS ENDED SEPTEMBER 30, – 2026 | Financial Results for the – Three and Nine Months Ended – September 30, 2026 and 2025 – STATEMENTS OF INCOME – (unaudited) – THREE MONTHS ENDED SEPTEMBER 30, – 2025 | Financial Results for the – Three and Nine Months Ended – September 30, 2026 and 2025 – STATEMENTS OF INCOME – (unaudited) – NINE MONTHS ENDED SEPTEMBER 30, – 2026 | Financial Results for the – Three and Nine Months Ended – September 30, 2026 and 2025 – STATEMENTS OF INCOME – (unaudited) – NINE MONTHS ENDED SEPTEMBER 30, – 2025 | |
|---|---|---|---|---|
| Net sales | 3,494,780 | 2,264,261 | 9,475,269 | 7,583,613 |
| Costs and expenses: | ||||
| Cost of sales | 1,619,479 | 1,311,192 | 4,629,733 | 3,775,122 |
| Operating expenses | 644,539 | 620,893 | 1,978,784 | 1,947,678 |
| Research and development expense | 121,834 | 117,104 | 361,250 | 339,366 |
| Total costs and expenses | 2,385,852 | 2,049,189 | 6,969,767 | 6,062,166 |
| Income from operations | 1,108,928 | 215,072 | 2,505,502 | 1,521,447 |
| Other Income: | ||||
| Investment income | 72,556 | 75,165 | 212,815 | 230,425 |
| Net (loss) gain on marketable securities | -7,916 | 36,238 | 58,191 | 73,164 |
| Settlement income | --- | --- | 339,493 | --- |
| Gain on sale of asset | --- | --- | 8,310 | --- |
| Total other income | 64,640 | 111,403 | 618,809 | 303,589 |
| Income before provision for income taxes | 1,173,568 | 326,475 | 3,124,311 | 1,825,036 |
| Provision for income taxes | 242,656 | 58,034 | 645,918 | 368,874 |
| Net income | 930,912 | 268,441 | 2,478,393 | 1,456,162 |
| Earnings per common share (Basic and Diluted) | 0.2 | 0.06 | 0.54 | 0.32 |
| Weighted average shares (Basic and Diluted) | 4,594,319 | 4,594,319 | 4,594,319 | 4,594,319 |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.